ga naar hoofdinhoud
Vademecum systeemtherapie Mammacarcinoom Literatuur en richtlijnen
Voorlezen

Literatuur

  1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG):  
    • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100.000 women from 86 randomised trials. Lancet. 2023; 401:1277-1292 
    • Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352
    • Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7.030 women from four randomised trials. Lancet Oncol. 2022; 23:382-92
    • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018; 19:27-39
    • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13.864 women in seven randomised trials. Lancet Oncol. 2021; 22:1139-50
    • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015; 386(10001): 1353-61
    • Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22.031 postmenopausal women already treated with at least 5 years of endocrine therapy Lancet. 2025; 406:603-614
  2. Gupta S et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: a phase III randomized controlled trial. Cancer Res 2023; 83:GS5-01
  3. Masuda N et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376(22):2147-59
  4. Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2):134-41
  5. Von Minckwitz G et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7):617-28
  6. Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1; 24(34):5381-7
  7. Sparano JA et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379:111-121
  8. Piccart MJ et al. Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X. Cancer Research February 2020; 80(4):GS4-05-GS4-05
  9. Sonke GS et al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature. 2024 Dec; 636(8042):474-480
  10. Gao JJ et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020 Feb; 21(2):250-260
  11. André F et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 Feb; 32(2):208-217
  12. Piccart et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2† . Ann Oncol. 2014 Dec; 25(12):2357-2362
  13. Carrick S et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005 Apr 18; (2):CD003372
  14. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006; 11(4):325-35
  15. Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23
  16. Swain SM et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372(8):724-34
  17. Krop IE et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017; 18(6):743-54
  18. Murthy RK et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020; 382(7):597-609
  19. Rimawi M. et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018; 36(28):2826-2835
  20. Lin NU et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020; 38(23):2610-2619
  21. Modi S et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020; 382(7):610-621
  22. Cortes J et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5; 396(10265):1817-1828
  23. Bardia A et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021; 384(16):1529-1541
  24. Trinh XB et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008; 90(1):17-22
  25. Lambertini M et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018; 36(19):1981-90

Commissie BOM adviezen

Ga naar de commissie BOM adviezen over mammacarcinoom. 

Richtlijnen

Ga naar de richtlijn Borstkanker in de FMS richtlijnen­database.

Ga naar de richtlijn Mammacarcinoom van VKGN - StOET.